RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025 $LCTX https://t.co/68Nm0Odqqr
ADS-TEC Energy Reports Full Year 2024 Financial Results and Provides Business Update https://t.co/6GT7cu2erb https://t.co/iEjJFEuHGN
Dentalcorp Reports First Quarter 2025 Results https://t.co/EvcnN4i0VE https://t.co/4tCeatH5cQ
Several companies across various sectors have announced their financial results for the first quarter of 2025. Aurinia Pharmaceuticals reported earnings per share of $0.16, surpassing the estimated $0.10, with sales of $62.4 million, beating the estimated $61.5 million. LUPKYNIS net product sales reached $60 million, and the company holds $313 million in cash and cash equivalents, reaffirming its full-year sales guidance of $250 million to $260 million. ImmunityBio reported a doubling of net revenue and a 150% increase in unit growth for the first quarter of 2025, attributing the strong sales momentum to the first quarter since receiving a J-code. BioXcel Therapeutics completed enrollment in its SERENITY pivotal Phase 3 safety trial for the acute treatment of agitation associated with bipolar disorders or schizophrenia, with topline data expected in the second half of 2025. In the automotive sector, Polestar reported an 84% revenue growth for the first quarter of 2025, alongside a significant improvement in gross margin to positive. Li Auto delivered 92,864 vehicles in the first quarter, near the upper end of its guidance range, with a year-on-year increase of 15.50%. In the healthcare sector, Amylyx Pharmaceuticals announced positive long-term results from the Phase 2 HELIOS clinical trial of AMX0035 in people with Wolfram Syndrome. CytomX Therapeutics announced positive interim data from the Phase 1 dose escalation study of its EpCAM antibody drug conjugate candidate, CX-2051, in patients with advanced colorectal cancer, and also priced a $100 million underwritten offering of common stock. Lineage Cell Therapeutics announced that 36-month results from the Phase 1/2a clinical study of RG6501 (OpRegen) in patients with geographic atrophy secondary to age-related macular degeneration will be presented at Clinical Trials at the Summit 2025.
